ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme

Study Purpose

Assess safety and tolerability of ADI-PEG 20 in combination with radiotherapy and Temozolomide in newly diagnosed GBM

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.

Searching Both is inclusive of interventional and observational studies.

Eligible Ages 20 Years - 75 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

1. Newly diagnosed, histologically confirmed GBM WHO Grade IV (any wildtype or mutant or gene type, except gliosarcoma), non-resectable or partially resected or resected. 2. Age 20
  • - 75 years.
3. Karnofsky Performance Status (KPS) ≥ 60. 4. Expected life expectancy ≥16 weeks. 5. Stable or decreasing corticosteroids (5 mg/day dexamethasone or equivalent) within 5 days before the first dose of ADI-PEG 20. 6. No prior systemic therapy, immunotherapy, investigational agent, or radiation therapy. 7. Recovered from any prior surgery and no major surgery within 2 weeks of initiating treatment (other than GBM surgery). Surgery for placement of vascular access devices is acceptable. 8. Female subjects and male subjects must be asked to use appropriate contraception for both the male and female for the duration of the study. Male partners of female subjects and female partners of male subjects must agree to use two forms of contraception or agree to refrain from intercourse for the duration of the study if they are of childbearing potential. Females of childbearing potential must not be pregnant at the start of the study, and a serum human chorionic gonadotropin (HCG) pregnancy test must be negative before entry into the study. If positive HCG pregnancy test, further evaluation to rule out pregnancy must be performed according to GCP before this subject is deemed eligible. Females not of childbearing potential must be post-menopausal (defined as cessation of regular menstrual period for at least 12 months). 9. Informed consent must be obtained prior to study initiation. 10. No concurrent investigational studies are allowed. 11. Absolute neutrophil count (ANC) ≥ 1500/μL. 12. Platelets ≥ 100,000/μL. 13. Serum uric acid ≤ 8 mg/dL (with or without medication control). 14. Creatinine clearance must be ≥ 40 mL/min/1.73 m2 (calculated using the Cockcroft-Gault equation: calculated creatinine clearance = (140-age (yrs)) × body weight (kg) (×0.85 if female) / 72 × serum creatinine (mg/dl). 15. Total bilirubin ≤ 2 x upper limit of normal. 16. ALT and AST ≤ 3 x upper limit of normal, unless liver metastases present then ≤ 5 x upper limit normal.

Exclusion Criteria:

1. Serious infection requiring treatment with systemically administered antibiotics at the time of study entrance, or an infection requiring systemic antibiotic therapy within 7 days prior to the first dose of study treatment. 2. Pregnancy or lactation. 3. Expected non-compliance. 4. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure (New York Heart Association Class III or IV), cardiac arrhythmia, or psychiatric illness, social . 5. Subjects with history of another primary cancer, including co-existent second malignancy, with the exception of: a) curatively resected non-melanoma skin cancer; b) curatively treated cervical carcinoma in situ; or c) other primary solid tumor with no known active disease present or in the opinion of the investigator will not affect patient outcome. 6. Subjects who had been treated with ADI-PEG 20 previously. 7. History of uncontrolled seizure disorder not related to underlying cancer. 8. Known HIV positivity, or active hepatitis B infection, or active hepatitis C infection (testing not required). 9. Allergy to pegylated compounds. 10. Allergy to E. coli drug products (such as GMCSF). 11. Allergy to TMZ or any of its components. 12. History of hypersensitivity to dacarbazine. 13. Placement of Gliadel wafer at surgery. 14. Having a co-existing condition requiring systemic treatment with either corticosteroids or immunosuppressive medication.

Trial Details

Trial ID:

This trial id was obtained from, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.


Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 1
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Polaris Group
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Kuo-Chen Wei, M.D.
Principal Investigator Affiliation Chang Gung Memorial Hospital
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Overall Status Recruiting
Countries Taiwan

The disease, disorder, syndrome, illness, or injury that is being studied.

Glioblastoma Multiforme (GBM)
Arms & Interventions


Experimental: ADI-PEG 20 plus Radiotherapy and Temozolomide

ADI-PEG 20 Dose: 18 and 36 mg/m2 given weekly Route of Administration: Intramuscular (IM) Radiotherapy Dose: 60 Gy in 30 daily (Monday-Friday) fractions of 2 Gy each; to start within 5 weeks of surgery (diagnostic and/or resection) Temozolomide Dose: 75 mg/m2 daily during radiotherapy; 150-200 mg/m2 for 5 days every 4 weeks (1 cycle) x 6 cycles during maintenance period Route of Administration: oral or intravenous


Drug: - ADI-PEG20

Investigational Medicine

Drug: - Temozolomide

Radiotherapy and TMZ are standard front-line therapy for newly diagnosed GBM.

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Taoyuan, Taiwan




Chang Gung Memorial Hospital, Linkou Branch

Taoyuan, , 333

Site Contact

Kuo-Chen Wei, M.D.

886-3-3281200 #2412

Stay Informed & Connected